Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer.

@article{Curtis2004RiskOM,
  title={Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer.},
  author={Rochelle E. Curtis and Daryl Michal Freedman and Mark E. Sherman and Joseph F. Jr. Fraumeni},
  journal={Journal of the National Cancer Institute},
  year={2004},
  volume={96 1},
  pages={70-4}
}
Recent studies have indicated that the tamoxifen-related risk of uterine corpus cancer may be especially high for some uncommon cell types, although the magnitude of risk has not been quantified. We evaluated data from 39 451 breast cancer patients diagnosed from 1980 through 2000 who were initially treated with tamoxifen and found that the overall risk of subsequent uterine corpus cancer was increased more than twofold (observed-to-expected ratio [O/E] = 2.17, 95% confidence interval [CI] = 1… CONTINUE READING